Epistem Announces a Three Year Collaboration with GlaxoSmithKline in Fibrosis Research
Epistem announces a three year biomarker collaboration with GlaxoSmithKline (NYSE: GSK) in the field of fibrosis research. The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp™ technology to facilitate building an in depth understanding of the disease.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.